不可切除的非转移性原发性黑色素瘤：抗程序性细胞死亡受体1治疗后完全缓解 - Suppr

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

作者信息

Lheure Coralie, Hoffmann Caroline, Kramkimel Nora, Plée Julie, Franck Nathalie, Vanhaecke Clélia, Goldman-Lévy Gabrielle, Bataillon Guillaume, Damotte Diane, Dupin Nicolas, Aractingi Selim, Grange Florent, Guégan Sarah

机构信息

Dermatology Department, Hôpital Cochin AP-HP, Paris, France.

出版信息

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.

DOI:10.2340/00015555-3028

PMID:30176045

Abstract

摘要

相似文献

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.

Resistance to PD-1 blockade in melanoma.

Lancet Oncol. 2016 Sep;17(9):e376. doi: 10.1016/S1470-2045(16)30372-2. Epub 2016 Jul 22.

MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.

J Dermatol Sci. 2020 Jan;97(1):77-79. doi: 10.1016/j.jdermsci.2019.11.010. Epub 2019 Nov 30.

Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.

J Am Acad Dermatol. 2020 Mar;82(3):770-772. doi: 10.1016/j.jaad.2019.11.017. Epub 2019 Nov 14.

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Cancer Immunol Immunother. 2020 May;69(5):717-730. doi: 10.1007/s00262-020-02497-9. Epub 2020 Feb 8.

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.

J Dermatol Sci. 2019 Jan;93(1):33-40. doi: 10.1016/j.jdermsci.2018.10.001. Epub 2018 Oct 6.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019.

Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.

J Oncol Pharm Pract. 2020 Mar;26(2):496-499. doi: 10.1177/1078155219858657. Epub 2019 Jun 29.

Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488.

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.

J Immunother Cancer. 2019 Jun 14;7(1):153. doi: 10.1186/s40425-019-0613-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

作者信息

机构信息

Dermatology Department, Hôpital Cochin AP-HP, Paris, France.

出版信息

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.

DOI:10.2340/00015555-3028

PMID:30176045

Abstract

摘要

相似文献

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.

Resistance to PD-1 blockade in melanoma.

Lancet Oncol. 2016 Sep;17(9):e376. doi: 10.1016/S1470-2045(16)30372-2. Epub 2016 Jul 22.

MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.

J Dermatol Sci. 2020 Jan;97(1):77-79. doi: 10.1016/j.jdermsci.2019.11.010. Epub 2019 Nov 30.

Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.

J Am Acad Dermatol. 2020 Mar;82(3):770-772. doi: 10.1016/j.jaad.2019.11.017. Epub 2019 Nov 14.

Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.

Cancer Immunol Immunother. 2020 May;69(5):717-730. doi: 10.1007/s00262-020-02497-9. Epub 2020 Feb 8.

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.

J Dermatol Sci. 2019 Jan;93(1):33-40. doi: 10.1016/j.jdermsci.2018.10.001. Epub 2018 Oct 6.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019.

Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.

J Oncol Pharm Pract. 2020 Mar;26(2):496-499. doi: 10.1177/1078155219858657. Epub 2019 Jun 29.

Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.

JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488.

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.

J Immunother Cancer. 2019 Jun 14;7(1):153. doi: 10.1186/s40425-019-0613-1.

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

作者信息

机构信息

出版信息

相似文献